Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Cancer|August 9, 2022
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlatesAndrew T Kuykendall, Qianxing Mo, David A Sallman, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 5, 2017
The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib ApprovalAndrew T Kuykendall, Chetasi Talati, Najla Al Ali, et al.
Annals of Hematology|November 29, 2023
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbiditiesNathan P Horvat, Enas F Abdallah, Zhuoer Xie, et al.
Therapeutic Advances in Hematology|February 21, 2024
Interferons in the treatment of myeloproliferative neoplasmsPankit Vachhani, John Mascarenhas, Prithviraj Bose, et al.
Annals of Hematology|December 1, 2017
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuationAndrew T Kuykendall, Savan Shah, Chetasi Talati, et al.
Annals of Hematology|October 8, 2021
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world dataAndrew T Kuykendall, Libo Sun, John Mascarenhas, et al.
Blood Neoplasia|October 2, 2025
A comparative assessment of molecular-based prognostic models in CMMLLuis E Aguirre, Najla Al Ali, Somedeb Ball, et al.
Leukemia|February 20, 2026
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy imagesAndrew Srisuwananukorn, Giuseppe Gaetano Loscocco, James M Dolezal, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 8, 2023
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic MalignanciesManish R Patel, William Donnellan, Michael Byrne, et al.
Blood Neoplasia|June 3, 2026
CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?Rami S Komrokji, Zena Komrokji, Najla H Al Ali, et al.
Pageof 6